Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports

Li,Ching‑Chun; Tsai,Hsiang‑Lin; Huang,Ching‑Wen; Yeh,Yung‑Sung; Tsai,Tzu‑Hsueh; Wang,Jaw‑Yuan

doi:10.3892/mco.2018.1712

November-2018 Volume 9 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2018 Volume 9 Issue 5

Full Size Image

Case Report Open Access

Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports

Authors:
- Ching‑Chun Li
- Hsiang‑Lin Tsai
- Ching‑Wen Huang
- Yung‑Sung Yeh
- Tzu‑Hsueh Tsai
- Jaw‑Yuan Wang
View Affiliations / Copyright

Affiliations: Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C., Department of Radiology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C.

Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 499-503
|
Published online on: September 6, 2018

https://doi.org/10.3892/mco.2018.1712
Expand metrics +

Abstract

Pseudoaneurysms are extremely rare in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI and bevacizumab in the first‑line setting. We herein present two rare cases of iatrogenic pseudoaneurysm developing in patients with mCRC after administration of FOLFIRI and bevacizumab. The first patient was a 57‑year‑old man who was admitted to our institution with intermittent massive bloody discharge following treatment with the 9th cycle of FOLFIRI combined with bevacizumab. Colonoscopic examination revealed sizeable bloody clots in the rectum, but no active bleeder was identified; however, the patient's hemoglobin level was found to be persistently decreased, so an angiography was performed. The angiography revealed a pseudoaneurysm with contrast extravasation from a branch of the left internal iliac artery. Embolization of the bleeding vessel was performed, and the post‑embolization angiography revealed no active bleeding. The second patient was a 65‑year‑old man who observed blood in the stool following treatment with the 5th cycle of FOLFIRI combined with bevacizumab. The angiography revealed a pseudoaneurysm in the superior rectal artery, and intravascular embolization with coils was performed. The patient was discharged without any signs of recurrent bleeding. Following a review of the relevant English literature, to the best of our knowledge, this is the first report on the formation of a bevacizumab‑related pseudoaneurysms in mCRC patients. The aim of this study was to alert clinicians to the possibility of this rare complication.

View Figures

View References

1	Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, et al: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol. 20:1842–1847. 2009. View Article : Google Scholar : PubMed/NCBI
2	Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004. View Article : Google Scholar : PubMed/NCBI
3	Gordon MS and Cunningham D: Managing patients treated with bevacizumab combination therapy. Oncology. 69 Suppl 3:S25–S33. 2005. View Article : Google Scholar
4	Heinzeling JH and Huerta S: Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: Incidence, etiology, and management. Curr Surg. 63:334–337. 2006. View Article : Google Scholar : PubMed/NCBI
5	You YN, Wolff BG, Boardman LA, Riegert-Johnson DL and Qin R: Peutz-Jeghers syndrome: A study of long-term surgical morbidity and causes of mortality. Fam Cancer. 9:609–616. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA and Feig BW: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 26:5254–5260. 2008. View Article : Google Scholar : PubMed/NCBI
7	Collins D, Ridgway PF, Winter DC, Fennelly D and Evoy D: Gastrointestinal perforation in metastatic carcinoma: A complication of bevacizumab therapy. Eur J Surg Oncol. 35:444–446. 2009. View Article : Google Scholar : PubMed/NCBI
8	Baeßler B, Maintz D and Persigehl T: Imaging procedure for colorectal cancer. Visc med. 32:166–171. 2016. View Article : Google Scholar : PubMed/NCBI
9	Cao D, Guo CH, Liu JW, Yang X and Li Q: Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer. Tumori. 101:46–51. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B and Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol. 23:3697–3705. 2005. View Article : Google Scholar : PubMed/NCBI
11	Pañares RL and Garcia AA: Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther. 7:433–445. 2007. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles